120 related articles for article (PubMed ID: 37976981)
1. Brain volume increase after discontinuing natalizumab therapy: Evidence for reversible pseudoatrophy.
Nakamura K; Elliott C; Lee H; Narayanan S; Arnold DL
Mult Scler Relat Disord; 2024 Jan; 81():105123. PubMed ID: 37976981
[TBL] [Abstract][Full Text] [Related]
2. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.
Vidal-Jordana A; Sastre-Garriga J; Pérez-Miralles F; Tur C; Tintoré M; Horga A; Auger C; Río J; Nos C; Edo MC; Arévalo MJ; Castilló J; Rovira A; Montalban X
Mult Scler; 2013 Aug; 19(9):1175-81. PubMed ID: 23319072
[TBL] [Abstract][Full Text] [Related]
3. The relationship between inflammatory activity and brain atrophy in natalizumab treated patients.
Magraner M; Coret F; Casanova B
Eur J Radiol; 2012 Nov; 81(11):3485-90. PubMed ID: 22391507
[TBL] [Abstract][Full Text] [Related]
4. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
Fuentes-Rumí L; Hernández-Clares R; Carreón-Guarnizo E; Valero-López G; Iniesta-Martinez F; Cabrera-Maqueda JM; León-Hernández A; Zamarro-Parra J; Morales-Ortiz A; Meca-Lallana JE
Mult Scler Relat Disord; 2020 Sep; 44():102311. PubMed ID: 32593958
[TBL] [Abstract][Full Text] [Related]
5. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
Ryerson LZ; Naismith RT; Krupp LB; Charvet LE; Liao S; Fisher E; de Moor C; Williams JR; Campbell N
Mult Scler Relat Disord; 2022 Feb; 58():103480. PubMed ID: 35051898
[TBL] [Abstract][Full Text] [Related]
6. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls.
Alvarez E; Nair KV; Hoyt BD; Seale RA; Sillau S; Miravalle A; Engebretson E; Schurr B; Corboy JR; Vollmer TL; Honce JM
Mult Scler Relat Disord; 2021 Oct; 55():103170. PubMed ID: 34364034
[TBL] [Abstract][Full Text] [Related]
7. Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.
van Lierop ZY; Noteboom S; Steenwijk MD; van Dam M; Toorop AA; van Kempen ZL; Moraal B; Barkhof F; Uitdehaag BM; Schoonheim MM; Teunissen CE; Killestein J
Mult Scler; 2022 Dec; 28(14):2231-2242. PubMed ID: 36062492
[TBL] [Abstract][Full Text] [Related]
8. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.
Zivadinov R; Rudick RA; De Masi R; Nasuelli D; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
Neurology; 2001 Oct; 57(7):1239-47. PubMed ID: 11591843
[TBL] [Abstract][Full Text] [Related]
9. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
Zivadinov R; Hojnacki D; Bergsland N; Kennedy C; Hagemeier J; Melia R; Ramasamy DP; Durfee J; Carl E; Dwyer MG; Weinstock-Guttman B
Eur J Neurol; 2016 Jun; 23(6):1101-9. PubMed ID: 26998905
[TBL] [Abstract][Full Text] [Related]
10. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b.
Rao AB; Richert N; Howard T; Lewis BK; Bash CN; McFarland HF; Frank JA
Neurology; 2002 Sep; 59(5):688-94. PubMed ID: 12221158
[TBL] [Abstract][Full Text] [Related]
11. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.
Miller DH; Soon D; Fernando KT; MacManus DG; Barker GJ; Yousry TA; Fisher E; O'Connor PW; Phillips JT; Polman CH; Kappos L; Hutchinson M; Havrdova E; Lublin FD; Giovannoni G; Wajgt A; Rudick R; Lynn F; Panzara MA; Sandrock AW;
Neurology; 2007 Apr; 68(17):1390-401. PubMed ID: 17452584
[TBL] [Abstract][Full Text] [Related]
12. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
Zivadinov R; Zorzon M; De Masi R; Nasuelli D; Cazzato G
J Neurol Sci; 2008 Apr; 267(1-2):28-35. PubMed ID: 17945260
[TBL] [Abstract][Full Text] [Related]
13. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study.
Horakova D; Dwyer MG; Havrdova E; Cox JL; Dolezal O; Bergsland N; Rimes B; Seidl Z; Vaneckova M; Zivadinov R
J Neurol Sci; 2009 Jul; 282(1-2):112-9. PubMed ID: 19168190
[TBL] [Abstract][Full Text] [Related]
14. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis.
Saida T; Hao Q; Kanda M; Tani Y
BMC Neurol; 2023 Aug; 23(1):311. PubMed ID: 37644415
[TBL] [Abstract][Full Text] [Related]
16. Inclusion of the Symbol Digit Modalities Test in a revised assessment of 'no evidence of disease activity-4 (NEDA-4)' in Latin-American patients with multiple sclerosis.
Guevara C; Villa E; Diaz V; Garrido C; Martinez M; Orellana P; Alarcón P; Silva-Rosas C; Barker GJ; Kempton MJ; de Grazia J
Mult Scler Relat Disord; 2020 Jul; 42():102076. PubMed ID: 32361478
[TBL] [Abstract][Full Text] [Related]
17. Disease reactivation after switching from natalizumab to daclizumab.
Uphaus T; Oberwittler C; Groppa S; Zipp F; Bittner S
J Neurol; 2017 Dec; 264(12):2491-2494. PubMed ID: 28975400
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
Polman CH; O'Connor PW; Havrdova E; Hutchinson M; Kappos L; Miller DH; Phillips JT; Lublin FD; Giovannoni G; Wajgt A; Toal M; Lynn F; Panzara MA; Sandrock AW;
N Engl J Med; 2006 Mar; 354(9):899-910. PubMed ID: 16510744
[TBL] [Abstract][Full Text] [Related]
19. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF; Defer G; Ryerson LZ; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Smirnakis K; Xiao S; Kong G; Kuhelj R; Campbell N;
Lancet Neurol; 2022 Jul; 21(7):608-619. PubMed ID: 35483387
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis--a prospective, non-randomized pilot study.
Portaccio E; Stromillo ML; Goretti B; Hakiki B; Giorgio A; Rossi F; De Leucio A; De Stefano N; Amato MP
Eur J Neurol; 2013 Jun; 20(6):986-90. PubMed ID: 23057658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]